Birdwatch Note
2024-04-30 05:13:24 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Author implies this is a new admission, whereas it is a new legal submission. "Rare" side effect is public info since Mar 2021: https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets Also trials were completed too. https://www.thehindu.com/news/national/covishield-completes-enrolment-of-phase-3-clinical-trials-under-partnership-of-icmr-and-serum-institute-of-india/article33081171.ece
Written by 3A6FB85A0B4FE977A56E2C4A3DC6983A3EC54B66BECF79E9F0A7F1A41EBB4498
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1785134088082608161
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1785175599310676454
- noteId - 1785175599310676454
- participantId -
- noteAuthorParticipantId - 3A6FB85A0B4FE977A56E2C4A3DC6983A3EC54B66BECF79E9F0A7F1A41EBB4498
- createdAtMillis - 1714454004490
- tweetId - 1785134088082608161
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Author implies this is a new admission, whereas it is a new legal submission. "Rare" side effect is public info since Mar 2021: https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets Also trials were completed too. https://www.thehindu.com/news/national/covishield-completes-enrolment-of-phase-3-clinical-trials-under-partnership-of-icmr-and-serum-institute-of-india/article33081171.ece
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-04-30 05:13:24 UTC (1714454004490) |
2024-04-30 10:26:47 UTC (1714472807396) |
CURRENTLY_RATED_HELPFUL | 2024-05-01 12:35:12 UTC (1714566912495) |
CURRENTLY_RATED_HELPFUL | 2024-04-30 10:26:47 UTC (1714472807396) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-04-30 12:20:19 -0500 | Rating Details | |
| 2024-04-30 11:02:54 -0500 | Rating Details | |
| 2024-04-30 10:23:58 -0500 | Rating Details | |
| 2024-04-30 05:08:24 -0500 | Rating Details | |
| 2024-04-30 03:12:44 -0500 | Rating Details | |
| 2024-04-30 03:06:38 -0500 | Rating Details | |
| 2024-04-30 02:53:53 -0500 | Rating Details | |
| 2024-04-30 02:52:44 -0500 | Rating Details | |
| 2024-04-30 02:51:48 -0500 | Rating Details | |
| 2024-04-30 02:42:57 -0500 | Rating Details | |
| 2024-04-30 02:36:18 -0500 | Rating Details | |
| 2024-04-30 02:22:48 -0500 | Rating Details | |
| 2024-04-30 02:18:22 -0500 | Rating Details | |
| 2024-04-30 00:47:50 -0500 | Rating Details | |
| 2024-04-30 00:42:03 -0500 | Rating Details | |
| 2024-04-30 00:32:21 -0500 | Rating Details | |
| 2024-05-01 10:37:25 -0500 | Rating Details | |
| 2024-05-01 04:15:48 -0500 | Rating Details | |
| 2024-05-01 01:07:29 -0500 | Rating Details | |
| 2024-04-30 21:02:53 -0500 | Rating Details | |
| 2024-04-30 15:46:40 -0500 | Rating Details | |
| 2024-04-30 05:04:51 -0500 | Rating Details | |
| 2024-04-30 03:21:52 -0500 | Rating Details | |
| 2024-04-30 03:16:53 -0500 | Rating Details | |
| 2024-04-30 03:01:56 -0500 | Rating Details | |
| 2024-04-30 02:39:38 -0500 | Rating Details | |
| 2024-04-30 02:39:33 -0500 | Rating Details | |
| 2024-04-30 02:34:36 -0500 | Rating Details | |
| 2024-04-30 02:24:21 -0500 | Rating Details | |
| 2024-04-30 02:22:53 -0500 | Rating Details | |
| 2024-04-30 02:15:52 -0500 | Rating Details | |
| 2024-04-30 02:06:54 -0500 | Rating Details | |
| 2024-04-30 01:54:01 -0500 | Rating Details | |
| 2024-04-30 01:53:00 -0500 | Rating Details | |
| 2024-04-30 01:47:44 -0500 | Rating Details | |
| 2024-04-30 01:23:24 -0500 | Rating Details | |
| 2024-04-30 01:09:08 -0500 | Rating Details | |
| 2024-04-30 00:39:47 -0500 | Rating Details | |
| 2024-04-30 21:58:00 -0500 | Rating Details | |
| 2024-04-30 15:17:16 -0500 | Rating Details | |
| 2024-04-30 14:22:14 -0500 | Rating Details | |
| 2024-04-30 12:37:11 -0500 | Rating Details | |
| 2024-04-30 12:12:25 -0500 | Rating Details | |
| 2024-04-30 11:07:54 -0500 | Rating Details | |
| 2024-04-30 07:24:15 -0500 | Rating Details | |
| 2024-04-30 03:34:18 -0500 | Rating Details | |
| 2024-04-30 02:47:26 -0500 | Rating Details | |
| 2024-04-30 02:29:16 -0500 | Rating Details | |
| 2024-04-30 02:27:31 -0500 | Rating Details | |
| 2024-04-30 02:21:33 -0500 | Rating Details | |
| 2024-04-30 01:59:25 -0500 | Rating Details | |
| 2024-04-30 01:43:18 -0500 | Rating Details | |
| 2024-04-30 00:37:23 -0500 | Rating Details | |
| 2024-04-30 20:21:10 -0500 | Rating Details | |
| 2024-04-30 16:58:31 -0500 | Rating Details | |
| 2024-04-30 08:01:47 -0500 | Rating Details | |
| 2024-04-30 07:59:37 -0500 | Rating Details | |
| 2024-04-30 07:42:58 -0500 | Rating Details | |
| 2024-04-30 06:03:10 -0500 | Rating Details | |
| 2024-04-30 04:39:11 -0500 | Rating Details | |
| 2024-04-30 02:51:55 -0500 | Rating Details | |
| 2024-04-30 02:48:10 -0500 | Rating Details | |
| 2024-04-30 02:45:11 -0500 | Rating Details | |
| 2024-04-30 02:40:21 -0500 | Rating Details | |
| 2024-04-30 02:36:28 -0500 | Rating Details | |
| 2024-04-30 02:33:34 -0500 | Rating Details | |
| 2024-04-30 02:18:18 -0500 | Rating Details | |
| 2024-04-30 02:06:56 -0500 | Rating Details | |
| 2024-04-30 02:04:12 -0500 | Rating Details | |
| 2024-04-30 01:59:12 -0500 | Rating Details | |
| 2024-04-30 01:56:57 -0500 | Rating Details | |
| 2024-04-30 01:45:50 -0500 | Rating Details | |
| 2024-04-30 01:45:09 -0500 | Rating Details | |
| 2024-04-30 01:10:08 -0500 | Rating Details | |
| 2024-04-30 06:11:34 -0500 | Rating Details | |
| 2024-04-30 07:48:34 -0500 | Rating Details | |
| 2024-04-30 03:26:18 -0500 | Rating Details | |
| 2024-04-30 01:01:31 -0500 | Rating Details |